Press Releases
February 04, 2013
Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results
- Fourth Quarter Product Sales of
- Full Year 2012 Product Sales of
- Full Year 2012 Operating Cash Flows of
Full year 2012 total revenues were
Product Sales
Product sales increased 18 percent to
Antiviral Franchise
Antiviral product sales increased 17 percent to
-
Atripla
Sales of Atripla increased 6 percent to$917.5 million for the fourth quarter of 2012, up from$863.3 million for the fourth quarter of 2011, reflecting sales growth of 6 percent in the U.S. and 5 percent inEurope . For 2012, Atripla sales increased 11 percent to$3.57 billion from$3.22 billion in 2011.
-
Truvada
Sales of Truvada increased 12 percent to$832.7 million for the fourth quarter of 2012, up from$746.0 million for the fourth quarter of 2011, reflecting sales growth of 16 percent in the U.S. and 6 percent inEurope . For 2012, Truvada sales increased 11 percent to$3.18 billion from$2.88 billion in 2011.
-
Viread
Sales of Viread® (tenofovir disoproxil fumarate) increased 19 percent to$226.7 million for the fourth quarter of 2012, up from$190.9 million for the fourth quarter of 2011, reflecting sales growth of 25 percent in the U.S. and 2 percent inEurope . For 2012, Viread sales increased 15 percent to$848.7 million from$737.9 million in 2011.
-
Complera/Eviplera
Sales of Complera/Eviplera grew to$117.8 million for the fourth quarter of 2012 compared to$19.7 million for the fourth quarter of 2011. For 2012, Complera/Eviplera sales increased to$342.2 million from$38.7 million in 2011. Complera was approved in the U.S. inAugust 2011 , and Eviplera was approved in theEuropean Union inNovember 2011 .
-
Stribild
Sales of our newest product, Stribild, which was launched in the U.S. inAugust 2012 , were$40.0 million for the fourth quarter of 2012.
Cardiovascular Franchise
Cardiovascular product sales increased 33 percent to
-
Letairis
Sales of Letairis® (ambrisentan) increased 48 percent to$116.1 million for the fourth quarter of 2012, up from$78.7 million for the fourth quarter of 2011. For 2012, Letairis sales increased 40 percent to$410.1 million from$293.4 million in 2011.
-
Ranexa
Sales of Ranexa® (ranolazine) increased 19 percent to$99.1 million for the fourth quarter of 2012, up from$83.7 million for the fourth quarter of 2011. For 2012, Ranexa sales increased 17 percent to$372.9 million from$320.0 million in 2011.
Other Products
Sales of other products increased 15 percent to
Royalty, Contract and Other Revenues
Royalty, contract and other revenues from collaborations were
Research and Development Expenses
Research and development (R&D) expenses for the fourth quarter of 2012
were
Selling, General and Administrative Expenses
Selling, general and administrative (SG&A) expenses for the fourth
quarter of 2012 were
Interest Expense and Other Income (Expense), Net
Interest expense for the fourth quarter of 2012 was
Income Taxes
The effective tax rate for 2012 was 28.7 percent compared to 23.6
percent for 2011. The increase was primarily due to acquisition-related
expenses which are not tax deductible and the expiration of the federal
R&D tax credit at the end of 2011. The non-GAAP effective tax rate for
2012 was 26.8 percent compared to 24.6 percent for 2011. In
Net Foreign Currency Exchange Impact
The net foreign currency exchange impact on fourth quarter 2012 product
sales and pre-tax earnings was a favorable
Cash,
As of December 31, 2012, Gilead had
Corporate Highlights
In December, Gilead's Board of Directors approved a two-for-one stock
split of the Company's outstanding common stock to be effected through a
stock dividend. Stockholders of record as of the close of business on
Also in December, Gilead and
Product and Pipeline Update
Antiviral Franchise
In
-
Interim data from the ongoing Phase 2 ELECTRON study examining a
12-week course of therapy with the investigational nucleotide
sofosbuvir (formerly referred to as GS-7977), the NS5A inhibitor
ledipasvir (formerly referred to as GS-5885) and ribavirin in patients
with genotype 1 chronic hepatitis C virus infection. Among
treatment-naïve patients receiving this combination, 100 percent
(n=25/25) remained HCV RNA undetectable four weeks after completing
therapy. These data were presented at the 63rd annual meeting of the
American Association for the Study of Liver Diseases inBoston . -
A Phase 3b clinical trial result from STaR (Single
Tablet Regimen),
the first head-to-head study comparing the single tablet regimens
Complera and Atripla in treatment-naïve adults with HIV infection.
Data demonstrated that Complera, which is marketed as Eviplera in the
European Union , is non-inferior to Atripla based on the proportion of patients with HIV RNA levels (viral load) < 50 copies/mL at 48 weeks. -
Two-year (96-week) results from two pivotal Phase 3 studies (Studies
102 and 103) evaluating the company's newest single tablet HIV
regimen, Stribild, among treatment-naïve patients with HIV-1
infection. Data showed that Stribild was non-inferior after two years
of treatment to two standard of care HIV regimens, Atripla in Study
102 and a protease-based regimen of ritonavir-boosted atazanavir plus
Truvada in Study 103. The results were presented in an oral session at
the 11th
International Congress on Drug Therapy in HIV Infection inGlasgow, United Kingdom . - Topline results from the Phase 3 POSITRON study examining a 12-week course of once-daily sofosbuvir plus ribavirin in patients with genotype 2 or 3 chronic HCV infection who are not candidates to take interferon. The study found that 78 percent of patients (n=161/207) remained HCV RNA undetectable 12 weeks after completing therapy. The safety profile of sofosbuvir was similar to that observed in previous studies, and there were few treatment discontinuations due to adverse events.
-
The European Commission granted marketing authorization for two new indications for once-daily Viread. The first new indication permits the use of Viread in combination with other antiretroviral agents for the treatment of HIV-1 infected pediatric patients aged 2 to less than 18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line pediatric agents. Additionally, Viread was approved for the treatment of chronic hepatitis B virus infection in adolescent patients aged 12 to less than 18 years with compensated liver disease and evidence of immune active disease.
In October, Gilead announced:
- A Phase 2 clinical trial evaluating tenofovir alafenamide (TAF), met its primary objective. TAF is an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection formerly referred to as GS-7340. The ongoing study compares a once-daily single tablet regimen containing TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg with Stribild among treatment-naïve adults.
Conference Call
At
A replay of the webcast will be archived on the company's website for
one year, and a phone replay will be available approximately two hours
following the call through
About Gilead
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. GAAP (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on pages 8 and 9.
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead's ability to achieve its
anticipated full year 2013 financial results; Gilead's ability to
sustain growth in revenues for its antiviral, cardiovascular and
respiratory franchises; continued fluctuations in ADAP purchases driven
by federal and state grant cycles which may not mirror patient demand
and may cause fluctuations in Gilead's earnings; the possibility of
unfavorable results from additional arms of the ELECTRON and QUANTUM
studies and subsequent clinical trials involving sofosbuvir and the
fixed-dose combination of sofosbuvir and ledipasvir; the levels of
inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Gilead's ability to submit new drug applications
for new product candidates in the timelines currently anticipated,
including sofosbuvir for the treatment of hepatitis C; Gilead's ability
to receive regulatory approvals in a timely manner or at all, for new
and current products; Gilead's ability to successfully commercialize its
products, including Complera/Eviplera and Stribild; Gilead's ability to
successfully develop its respiratory, cardiovascular and
oncology/inflammation franchises; safety and efficacy data from clinical
studies may not warrant further development of Gilead's product
candidates, including sofosbuvir; the potential for additional austerity
measures in European countries that may increase the amount of discount
required on Gilead's products; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency
exchange impact on Gilead's future revenues and pre-tax earnings;
Gilead's ability to consummate the purchase of YM, including the risk
that a governmental entity may prohibit, delay or refuse to grant
approval for the consummation of the transaction; Gilead's ability to
advance Pharmasset's or YM's product pipeline; and other risks
identified from time to time in Gilead's reports filed with the
Gilead owns or has rights to various trademarks, copyrights and trade
names used in our business, including the following: GILEAD®,
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb &
LEXISCAN® is a registered trademark belonging to
MACUGEN® is a registered trademark belonging to
SUSTIVA® is a registered trademark of
TAMIFLU® is a registered trademark belonging to
For more information on
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in thousands, except per share amounts) |
||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 2,510,811 | $ | 2,133,334 | $ | 9,398,371 | $ | 8,102,359 | ||||||||
| Royalty, contract and other revenues | 77,474 | 67,044 | 304,146 | 283,026 | ||||||||||||
| Total revenues | 2,588,285 | 2,200,378 | 9,702,517 | 8,385,385 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 675,818 | 584,447 | 2,471,363 | 2,124,410 | ||||||||||||
| Research and development | 439,659 | 402,236 | 1,759,945 | 1,229,151 | ||||||||||||
| Selling, general and administrative | 365,825 | 346,219 | 1,461,034 | 1,241,983 | ||||||||||||
| Total costs and expenses | 1,481,302 | 1,332,902 | 5,692,342 | 4,595,544 | ||||||||||||
| Income from operations | 1,106,983 | 867,476 | 4,010,175 | 3,789,841 | ||||||||||||
| Interest expense | (85,906 | ) | (74,998 | ) | (360,916 | ) | (205,418 | ) | ||||||||
| Other income (expense), net | 1,386 | 26,365 | (37,279 | ) | 66,581 | |||||||||||
| Income before provision for income taxes | 1,022,463 | 818,843 | 3,611,980 | 3,651,004 | ||||||||||||
| Provision for income taxes | 263,504 | 157,084 | 1,038,381 | 861,945 | ||||||||||||
| Net income | 758,959 | 661,759 | 2,573,599 | 2,789,059 | ||||||||||||
| Net loss attributable to noncontrolling interest | 3,582 | 3,386 | 17,967 | 14,578 | ||||||||||||
| Net income attributable to Gilead | $ | 762,541 | $ | 665,145 | $ | 2,591,566 | $ | 2,803,637 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic(1) | $ | 0.50 | $ | 0.44 | $ | 1.71 | $ | 1.81 | ||||||||
| Net income per share attributable to Gilead common stockholders - diluted(1) | $ | 0.47 | $ | 0.43 | $ | 1.64 | $ | 1.77 | ||||||||
| Shares used in per share calculation - basic(1) | 1,517,208 | 1,504,448 | 1,514,621 | 1,549,806 | ||||||||||||
| Shares used in per share calculation - diluted(1) | 1,636,939 | 1,532,652 | 1,582,549 | 1,580,236 | ||||||||||||
|
(1) Net income per share and the number of shares used in the per share calculations for all periods presented reflect the two-for-one stock split in the form of a stock dividend declared on December 10, 2012 which took effect on January 25, 2013. |
||||||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in thousands, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 675,818 | $ | 584,447 | $ | 2,471,363 | $ | 2,124,410 | ||||||||
| Stock-based compensation expenses | (977 | ) | (668 | ) | (7,061 | ) | (8,433 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (15,837 | ) | (17,407 | ) | (63,346 | ) | (69,629 | ) | ||||||||
| Non-GAAP cost of goods sold | $ | 659,004 | $ | 566,372 | $ | 2,400,956 | $ | 2,046,348 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 73.2 | % | 72.6 | % | 73.8 | % | 73.8 | % | ||||||||
| Stock-based compensation expenses | — | — | 0.1 | % | 0.1 | % | ||||||||||
| Acquisition related-amortization of purchased intangibles | 0.6 | % | 0.8 | % | 0.7 | % | 0.9 | % | ||||||||
| Non-GAAP product gross margin(1) | 73.8 | % | 73.4 | % | 74.5 | % | 74.8 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 439,659 | $ | 402,236 | $ | 1,759,945 | $ | 1,229,151 | ||||||||
| Stock-based compensation expenses | (24,886 | ) | (18,961 | ) | (187,100 | ) | (73,490 | ) | ||||||||
| Restructuring expenses | (89 | ) | (78 | ) | (7,411 | ) | (1,438 | ) | ||||||||
| Acquisition related-transaction costs | — | — | (345 | ) | (446 | ) | ||||||||||
| Acquisition related-contingent consideration remeasurement | (5,353 | ) | (7,286 | ) | (69,469 | ) | (8,484 | ) | ||||||||
| Acquisition related-IPR&D Impairment | — | (26,630 | ) | — | (26,630 | ) | ||||||||||
| Non-GAAP research and development expenses | $ | 409,331 | $ | 349,281 | $ | 1,495,620 | $ | 1,118,663 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 365,825 | $ | 346,219 | $ | 1,461,034 | $ | 1,241,983 | ||||||||
| Stock-based compensation expenses | (31,264 | ) | (26,634 | ) | (208,501 | ) | (110,455 | ) | ||||||||
| Restructuring expenses | 63 | (1,233 | ) | (13,136 | ) | (7,287 | ) | |||||||||
| Acquisition related-transaction costs | (1,236 | ) | (28,466 | ) | (12,332 | ) | (29,744 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (1,125 | ) | — | (1,125 | ) | — | ||||||||||
| Non-GAAP selling, general and administrative expenses | $ | 332,263 | $ | 289,886 | $ | 1,225,940 | $ | 1,094,497 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 42.8 | % | 39.4 | % | 41.3 | % | 45.2 | % | ||||||||
| Stock-based compensation expenses | 2.2 | % | 2.1 | % | 4.2 | % | 2.3 | % | ||||||||
| Restructuring expenses | 0.0 | % | 0.1 | % | 0.2 | % | 0.1 | % | ||||||||
| Acquisition related-transaction costs | 0.0 | % | 1.3 | % | 0.1 | % | 0.4 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 0.7 | % | 0.8 | % | 0.7 | % | 0.8 | % | ||||||||
| Acquisition related-contingent consideration remeasurement | 0.2 | % | 0.3 | % | 0.7 | % | 0.1 | % | ||||||||
| Acquisition related-IPR&D Impairment | — | 1.2 | % | — | 0.3 | % | ||||||||||
| Non-GAAP operating margin(1) | 45.9 | % | 45.2 | % | 47.2 | % | 49.2 | % | ||||||||
| Interest expense reconciliation: | ||||||||||||||||
| GAAP interest expense | $ | (85,906 | ) | $ | (74,998 | ) | $ | (360,916 | ) | $ | (205,418 | ) | ||||
| Acquisition related-transaction costs | — | 23,817 | 7,333 | 23,817 | ||||||||||||
| Non-GAAP interest expense | $ | (85,906 | ) | $ | (51,181 | ) | $ | (353,583 | ) | $ | (181,601 | ) | ||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead, net of tax | $ | 762,541 | $ | 665,145 | $ | 2,591,566 | $ | 2,803,637 | ||||||||
| Stock-based compensation expenses | 42,423 | 35,303 | 346,705 | 145,053 | ||||||||||||
| Restructuring expenses | 101 | 1,010 | 15,038 | 6,579 | ||||||||||||
| Acquisition related-transaction costs | 981 | 12,798 | 14,646 | 14,522 | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 12,605 | 13,275 | 47,186 | 52,500 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 4,783 | 7,584 | 68,899 | 8,484 | ||||||||||||
| Acquisition related-IPR&D Impairment | — | 7,989 | — | 7,989 | ||||||||||||
| Non-GAAP net income attributable to Gilead, net of tax | $ | 823,434 | $ | 743,104 | $ | 3,084,040 | $ | 3,038,764 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 0.47 | $ | 0.43 | $ | 1.64 | $ | 1.77 | ||||||||
| Stock-based compensation expenses | 0.03 | 0.02 | 0.22 | 0.09 | ||||||||||||
| Restructuring expenses | 0.00 | 0.00 | 0.01 | 0.00 | ||||||||||||
| Acquisition related-transaction costs | 0.00 | 0.01 | 0.01 | 0.01 | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 0.01 | 0.01 | 0.03 | 0.03 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 0.00 | 0.00 | 0.04 | 0.01 | ||||||||||||
| Acquisition related-IPR&D Impairment | — | 0.01 | — | 0.01 | ||||||||||||
| Non-GAAP diluted earnings per share(1) | $ | 0.50 | $ | 0.49 | $ | 1.95 | $ | 1.93 | ||||||||
| Shares used in per share calculation (diluted)(2) reconciliation: | ||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 1,636,939 | 1,532,652 | 1,582,549 | 1,580,236 | ||||||||||||
| Share impact of current stock-based compensation rules | (1,965 | ) | (4,266 | ) | (2,522 | ) | (4,032 | ) | ||||||||
| Non-GAAP shares used in per share calculation (diluted) | 1,634,974 | 1,528,386 | 1,580,027 | 1,576,204 | ||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 16,814 | $ | 18,075 | $ | 70,407 | $ | 78,062 | ||||||||
| Research and development expenses adjustments | 30,328 | 52,955 | 264,325 | 110,488 | ||||||||||||
| Selling, general and administrative expenses adjustments | 33,562 | 56,333 | 235,094 | 147,486 | ||||||||||||
| Interest expense adjustments | — | 23,817 | 7,333 | 23,817 | ||||||||||||
| Total non-GAAP adjustments before tax | 80,704 | 151,180 | 577,159 | 359,853 | ||||||||||||
| Income tax effect | (19,811 | ) | (73,221 | ) | (84,685 | ) | (124,726 | ) | ||||||||
| Total non-GAAP adjustments after tax | $ | 60,893 | $ | 77,959 | $ | 492,474 | $ | 235,127 | ||||||||
| (1) Amounts may not sum due to rounding | ||||||||||||||||
| (2) The earnings per share calculation and the number of shares used in the per share calculation reflect the two-for-one stock split in the form of a stock dividend declared on December 10, 2012 which took effect on January 25, 2013. | ||||||||||||||||
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
|||||||
| December 31, | December 31, | ||||||
| 2012 | 2011(1) | ||||||
| (unaudited) | |||||||
| Cash, cash equivalents and marketable securities | $ | 2,582,086 | $ | 9,963,972 | |||
| Accounts receivable, net | 1,751,388 | 1,951,167 | |||||
| Inventories | 1,744,982 | 1,389,983 | |||||
| Property, plant and equipment, net | 1,100,259 | 774,406 | |||||
| Intangible assets, net | 11,736,393 | 1,062,864 | |||||
| Goodwill | 1,060,919 | 1,004,102 | |||||
| Other assets | 1,263,811 | 1,156,640 | |||||
| Total assets | $ | 21,239,838 | $ | 17,303,134 | |||
| Current liabilities | $ | 4,270,020 | $ | 2,514,790 | |||
| Long-term liabilities | 7,418,949 | 7,920,995 | |||||
| Stockholders’ equity(2) | 9,550,869 | 6,867,349 | |||||
| Total liabilities and stockholders’ equity | $ | 21,239,838 | $ | 17,303,134 | |||
|
(1) Derived from the audited consolidated financial statements as of December 31, 2011. |
|||||||
|
(2) As of December 31, 2012, there were 1,519,163 shares of common stock issued and outstanding. The number of common shares outstanding reflects the two-for-one stock split in the form of a stock dividend declared on December 10, 2012 which took effect on January 25, 2013. |
|||||||
|
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in thousands) |
|||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| 2012 | 2011 | 2012 | 2011 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Atripla – U.S. | $ | 579,979 | $ | 547,469 | $ | 2,252,655 | $ | 2,022,049 | |||||||
| Atripla – Europe | 281,476 | 267,501 | 1,102,570 | 1,042,668 | |||||||||||
| Atripla – Other International | 56,031 | 48,345 | 219,258 | 159,801 | |||||||||||
| 917,486 | 863,315 | 3,574,483 | 3,224,518 | ||||||||||||
| Truvada – U.S. | 431,715 | 373,574 | 1,612,506 | 1,385,411 | |||||||||||
| Truvada – Europe | 334,907 | 316,953 | 1,315,533 | 1,257,265 | |||||||||||
| Truvada – Other International | 66,102 | 55,475 | 253,071 | 232,465 | |||||||||||
| 832,724 | 746,002 | 3,181,110 | 2,875,141 | ||||||||||||
| Viread – U.S. | 105,192 | 84,321 | 387,929 | 324,741 | |||||||||||
| Viread – Europe | 84,585 | 83,250 | 335,540 | 328,312 | |||||||||||
| Viread – Other International | 36,904 | 23,297 | 125,228 | 84,814 | |||||||||||
| 226,681 | 190,868 | 848,697 | 737,867 | ||||||||||||
| Complera / Eviplera – U.S. | 84,328 | 19,463 | 280,070 | 38,507 | |||||||||||
| Complera / Eviplera – Europe | 27,932 | 85 | 52,703 | 85 | |||||||||||
| Complera / Eviplera – Other International | 5,554 | 155 | 9,427 | 155 | |||||||||||
| 117,814 | 19,703 | 342,200 | 38,747 | ||||||||||||
| Stribild – U.S. | 40,022 | — | 57,533 | — | |||||||||||
| Stribild – Other International | 3 | — | 3 | — | |||||||||||
| 40,025 | — | 57,536 | — | ||||||||||||
| Hepsera – U.S. | 9,766 | 14,450 | 43,362 | 57,259 | |||||||||||
| Hepsera – Europe | 12,907 | 14,845 | 54,291 | 75,138 | |||||||||||
| Hepsera – Other International | 2,835 | 3,001 | 10,662 | 12,282 | |||||||||||
| 25,508 | 32,296 | 108,315 | 144,679 | ||||||||||||
| Emtriva – U.S. | 4,951 | 4,734 | 18,531 | 17,216 | |||||||||||
| Emtriva – Europe | 1,544 | 1,698 | 6,713 | 6,860 | |||||||||||
| Emtriva – Other International | 1,135 | 1,357 | 4,205 | 4,688 | |||||||||||
| 7,630 | 7,789 | 29,449 | 28,764 | ||||||||||||
| Total Antiviral products – U.S. | 1,255,953 | 1,044,011 | 4,652,586 | 3,845,183 | |||||||||||
| Total Antiviral products – Europe | 743,351 | 684,332 | 2,867,350 | 2,710,328 | |||||||||||
| Total Antiviral products – Other International | 168,564 | 131,630 | 621,854 | 494,205 | |||||||||||
| 2,167,868 | 1,859,973 | 8,141,790 | 7,049,716 | ||||||||||||
| Letairis | 116,078 | 78,661 | 410,054 | 293,426 | |||||||||||
| Ranexa | 99,127 | 83,651 | 372,949 | 320,004 | |||||||||||
| AmBisome | 90,781 | 80,784 | 346,646 | 330,156 | |||||||||||
| Other products | 36,957 | 30,265 | 126,932 | 109,057 | |||||||||||
| 342,943 | 273,361 | 1,256,581 | 1,052,643 | ||||||||||||
| Total product sales | $ | 2,510,811 | $ | 2,133,334 | $ | 9,398,371 | $ | 8,102,359 | |||||||
Source:
Gilead Sciences, Inc.
Robin Washington, 650-522-5688 (Investors)
Patrick
O'Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)